Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched Targeted Therapy Based on Biomarkers Identified by ctDNA Genotyping By Ogkologos - November 11, 2024 638 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SCRUM-Japan GOZILA study Source RELATED ARTICLESMORE FROM AUTHOR Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less FDA Approves Acalabrutinib with Venetoclax for CLL or SLL No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC MOST POPULAR Determination of the Incidence of Driver Mutations in Patients with NSCLC... March 24, 2021 Data Collection Analysis Demonstrates Changes in Lung Cancer Management Throughout the... March 26, 2021 Pembrolizumab Does Not Prolong Overall Survival Compared to Chemotherapy in Platinum-Pretreated... September 20, 2021 EMA Recommends Extension of Therapeutic Indications for Durvalumab and Adopts a... December 23, 2022 Load more HOT NEWS Making Important Decisions During Cancer: A Survivor’s Story A Follow-Up Not Inferior to Radioiodine Ablation in Patients with Low-Risk... TIL Densities Association with Disease-Free Survival Differs by Primary Tumour Sidedness... Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly...
